Resources
BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).5
Prescribing information and adverse event reporting can be found using the link above.
For healthcare professionals
BOTOX® Injection Site Anatomy Poster with Muscles and Nerves
This poster shows a summary of the PREEMPT treatment paradigm, a culmination of over 10 years’ experience of migraine research, optimised to help patients with chronic migraine maximise their likelihood of a beneficial effect.
To receive a copy of this poster, please submit your details on the Contact Us page and tick BOTOX® Injection Site Anatomy Poster with Muscles and Nerves.
BOTOX® dosage and administration guide
This guide provides a summary of the dosage and administration for BOTOX® and offers additional useful information on contraindications, injection sites, and recommended treatment intervals.
To receive a copy of this guide, please submit your details on the Contact Us page and tick BOTOX® dosage and administration guide.
Educational modules for healthcare professionals – E-learning
BOTOX® (Botulinum Toxin Type A) Chronic Migraine E-learning Module 1:
Understanding Chronic Migraine: Diagnosis and Management
This module, designed for UK healthcare professionals involved in the management of patients with CM includes; how to achieve a differential diagnosis of CM, the goals of CM treatment, a summary of the available treatment options and how to manage medication overuse headache.
BOTOX® (Botulinum Toxin Type A) Chronic Migraine E-learning Module 2:
Evidence Base for BOTOX® in Chronic Migraine
This module, designed for UK healthcare professionals involved in the management of patients with CM, provides an overview of the pivotal clinical trials and real-world evidence supporting the use of BOTOX® for the treatment of CM.
BOTOX® (Botulinum Toxin Type A) Chronic Migraine E-learning Module 3:
Reconstitution and Administration of BOTOX® for Chronic Migraine
This module, designed for UK healthcare professionals involved in the management of patients with CM includes; the reconstitution and administration of BOTOX® for patients with CM, the PREEMPT injection paradigm and protocols, along with considerations for before, during and after the BOTOX® injection procedure.
BOTOX® (Botulinum Toxin Type A) Chronic Migraine E-learning Module 4:
Improving Clinic Efficiency
This module, designed for UK healthcare professionals involved in the management of patients with CM, explores best practice tips and techniques regarding BOTOX® clinic setup and layout and provides guidance on how to improve clinic efficiency.
Educational modules for peer-to-peer meetings
These educational modules have been designed to be used at peer-to-peer meetings, presented either by a healthcare professional or by an AbbVie Key Account Manager.
If you are interested in discussion these modules further, please submit your details on the Contact Us page. Tick the appropriate box which relates to the module(s) in which you are interested, and a member of the AbbVie team will be in contact with you. The following educational modules are available:
- Chronic migraine overview, prevalence and burden
- Ensuring an accurate diagnosis of chronic migraine
- Treatment options and management
- Pathophysiology of chronic migraine and mechanism of action of BOTOX®
- Efficacy and safety of BOTOX® in chronic migraine
- The BOTOX® injection procedure in chronic migraine
- The chronic migraine patient pathway
Resources for your patients
Patient Guide for the Treatment of Chronic Migraine with BOTOX®
To support your chronic migraine patients treated with BOTOX®, this guide provides information on how the treatment works, what to expect during and after treatment and potential side-effects.
The information in this guide does not replace the Patient Information Leaflet (PIL) that is enclosed with the prescribed medication.
To receive a copy of this guide, please submit your details on the Contact Us page and tick Chronic Migraine Patient Guide.
CM: chronic migraine; GIRFT: Getting It Right First Time.
Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
Date of preparation: September 2024. UK-BCM-240091
